Alendronate for the prevention of osteoporosis in ankylosing spondylitis
Phase 2
- Conditions
- Ankylosing spondylitis.Ankylosing spondylitis
- Registration Number
- IRCT201212206975N3
- Lead Sponsor
- Vice chancellor for research, Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Schober index=5; Normal hip joint in the pelvic radiography; Absence or rarity of syndesmophyte in the spine radiography (Taylor index=1); Normal bone density or mild osteopenia (T-score=-1.5)
Exclusion criteria:
Use of drugs which increase bone density like bisphosphonates; Use of steroids and biological agents; Coexistence of other disease which decreases bone density: including hyperparathyroidism, diabetes, hyper and hypothyroidism, osteomalasia, liver failure, renal failure
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone density. Timepoint: 12 months after intervention (at the end of study). Method of measurement: Bone mineral density measurement as gram/cm² by the DEXA method with Hologic QRD model instrument from lumbar and pelvic area.
- Secondary Outcome Measures
Name Time Method Osteoporotic fracture. Timepoint: Every 3 months until 12 months. Method of measurement: History, physical examination, and radiography.